# Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

> **NCT03342898** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 900 (actual)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** YF-17D
- **BIOLOGICAL:** TDV
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03342898
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-28
- **Primary completion:** 2018-05-09
- **Final completion:** 2019-05-22
- **Target enrollment:** 900 (ACTUAL)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03342898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03342898, "Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03342898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*